Caris Life, Lustgarten Foundation Collaborate

Caris Life Sciences, a leading innovator in molecular science, and the Lustgarten Foundation, the largest private funder of pancreatic cancer research, are collaborating to support a clinical trial evaluating the impact of immunotherapy in the treatment of pancreatic cancer.

Caris is providing clinical trial enrollment services to identify potential trial candidates based on biomarker expression results and facilitate communication between treating physicians and study investigators. The Lustgarten Foundation is a sponsor of the study for pancreatic cancer patients in support of its mission to advance scientific and medical research related to the diagnosis, treatment and cure of pancreatic cance

While pancreatic cancer is an extremely challenging disease to treat, recent advances in immunotherapies are rapidly changing the way cancer is being treated. The phase 2 study of MK-3475 in patients with microsatellite unstable tumors (NCT01876511), is investigating whether MK-3475, an immunotherapy that blocks negative signals to T cells, is an effective anti-tumor activity agent for MSI-High tumors. The study is also measuring alternative biomarkers correlating to MSI status, including Mismatch Repair Proteins (MMR), MLH1, MSH2, MSH6 and PMS2, among others.

Caris' MI trials services will identify MMR positive patients in real-time through the Caris Molecular IntelligenceĀ® tumor profiling service, which has profiled more than 110,000 clinical cases to date and helps physicians and researchers more effectively evaluate therapy options and clinical trial opportunities. Upon positive biomarker expression status, MI trials medical staff will facilitate communication between treating physicians and study investigators.